Advanced Search

Tyrosine Kinase Receptors Stocks List

Symbol Grade Name % Change
MACK D Merrimack Pharmaceuticals, Inc. -6.22
PBYI F Puma Biotechnology Inc -5.59
FPRX C Five Prime Therapeutics, Inc. -3.68
BPMC D Blueprint Medicines Corporation 2.22
DCPH F Deciphera Pharmaceuticals, Inc. 2.79
BBIO A BridgeBio Pharma, Inc. 8.52
BDTX F Black Diamond Therapeutics, Inc. -1.13
ZNTL D Zentalis Pharmaceuticals, Inc. 4.03
FUSN F Fusion Pharmaceuticals Inc. -2.67
RLAY F Relay Therapeutics, Inc. -2.48
PRLD F Prelude Therapeutics Incorporated -3.11
VOR F Vor Biopharma Inc. -16.86
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Cancer Biopharmaceutical Clinical Development Epidermal Growth Factor Receptor Fibroblast Growth Factor Receptor Protein Kinase Inhibitor Solid Tumors Tyrosine Kinase Biotechnology Breast Cancer Fibroblast Growth Factor Her2 Her2/Neu Treatment Of Breast Cancer Antibodies Blastoma Cancer Cell Cancers Cell Biology Drugs

Related ETFs - A few ETFs which own one or more of the above listed Tyrosine Kinase Receptors stocks.

Symbol Grade Name Weight
SBIO D ALPS Medical Breakthroughs ETF 5.27
PBE D PowerShares Dynamic Biotech & Genome 4.48
IBBJ D Defiance Nasdaq Junior Biotechnology ETF 4.21
XBI D SPDR Series Trust SPDR S&P Biotech ETF 4.19
IDNA D iShares Genomics Immunology and Healthcare ETF 4.11
View all Tyrosine Kinase Receptors related ETFs...
Compare ETFs
  • Compare PBE to IDNA
  • Compare SBIO to IBBJ
  • Compare SBIO to IDNA

    • Recent Signals

    Date Stock Signal Type
    2021-02-26 BBIO MACD Bullish Signal Line Cross Bullish
    2021-02-26 BBIO Pocket Pivot Bullish Swing Setup
    2021-02-26 BBIO Expansion Pivot Buy Setup Bullish Swing Setup
    2021-02-26 BBIO 180 Bullish Setup Bullish Swing Setup
    2021-02-26 BBIO 20 DMA Support Bullish
    2021-02-26 BBIO Crossed Above 50 DMA Bullish
    2021-02-26 BDTX 20 DMA Support Bullish
    2021-02-26 BPMC 20 DMA Resistance Bearish
    2021-02-26 BPMC Pocket Pivot Bullish Swing Setup
    2021-02-26 DCPH Slingshot Bearish Bearish Swing Setup
    2021-02-26 FPRX Slingshot Bullish Bullish Swing Setup
    2021-02-26 FUSN Lizard Bullish Bullish Day Trade Setup
    2021-02-26 FUSN Fell Below 20 DMA Bearish
    2021-02-26 FUSN Hammer Candlestick Bullish
    2021-02-26 FUSN Doji - Bullish? Reversal
    2021-02-26 MACK MACD Bearish Centerline Cross Bearish
    2021-02-26 MACK 1,2,3 Pullback Bullish Bullish Swing Setup
    2021-02-26 PBYI 200 DMA Resistance Bearish
    2021-02-26 PBYI Expansion Breakdown Bearish Swing Setup
    2021-02-26 PBYI Lower Bollinger Band Walk Weakness
    2021-02-26 ZNTL Stochastic Reached Overbought Strength
    2021-02-26 ZNTL Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
    2021-02-26 ZNTL Crossed Above 200 DMA Bullish

    Recent News for Tyrosine Kinase Receptors Stocks

    Date Stock Title
    Feb 28 BBIO BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A
    Feb 27 VOR The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
    Feb 27 BPMC 15 Fastest Growing Biotech Companies in the US
    Feb 27 RLAY Relay Therapeutics: A Long-Term Position In Data-Driven Drug Developer Looks Attractive
    Feb 26 FPRX Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
    Feb 26 PBYI Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall
    Feb 26 PBYI Puma Biotechnology and CANbridge terminate NERLYNX license agreement
    Feb 26 BBIO Is a Surprise Coming for BridgeBio Pharma (BBIO) This Earnings Season?
    Feb 26 PBYI The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida
    Feb 26 PBYI Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q4 2020 Results - Earnings Call Transcript
    Feb 25 PBYI Puma Biotechnology EPS misses by $0.05, misses on revenue
    Feb 25 PBYI Puma Biotechnology and Pierre Fabre amend NERLYNX license agreement
    Feb 25 PBYI Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
    Feb 25 PBYI Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
    Feb 25 BBIO BridgeBio Pharma EPS misses by $0.16, misses on revenue
    Feb 25 BBIO BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update
    Feb 25 ZNTL Zentalis and Tempus ink research collaboration deal
    Feb 25 ZNTL Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
    Feb 24 PBYI Puma Biotechnology Q4 2020 Earnings Preview
    Feb 24 BBIO BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Biopharmaceutical Clinical Development Epidermal Growth Factor Receptor Fibroblast Growth Factor Receptor Protein Kinase Inhibitor Solid Tumors Tyrosine Kinase Biotechnology Breast Cancer Fibroblast Growth Factor Her2 Her2/Neu Treatment Of Breast Cancer Antibodies Blastoma Cancer Cell Cancers Cell Biology Drugs

    Browse All Tags